Glaxo Smith Kline LLC, Durham, North Carolina, was awarded a $651,094,500 firm-fixed-price contract for Sotrovimab Therapeutic for the treatment of COVID-19. Bids were solicited via the internet with one received. Work will be performed in Durham, North Carolina, with an estimated completion date of March 31, 2022. Fiscal 2010 Defense Production Act funds in the amount of $651,094,500 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity (W58P05-22-C-0002). (Awarded Nov. 15, 2021)

GlaxoSmithKline (GSK) gives anxiety, asthma, and other ailments the ax. One of the top five pharmaceutical firms in the world, GSK’s bestsellers include respiratory, neurological, cardiovascular and dermatology drugs, as well as vaccines and antivirals and consumer healthcare products. It boasts four billion-dollar drugs: Advair/Seretide, its stalwart asthma medication; Relvar/Breo Ellipta, a chronic obstructive pulmonary disease treatment; and two HIV medications, Triumeq and Tivicay. In the consumer healthcare business, GSK racks up big sales from its Sensodyne toothpaste brand, joint-pain relief medicine Voltaren, and fever relief medicine Panadol. Based in the UK, GSK has customers across the globe. (www.dnb.com)